Dr.NEET MEHTA

Dr. MURALEEDHARA R.

Abstract

CHED is a rare, autosomal recessive, monogenic corneal condition with variable expressivity. This video focuses on applying newer investigational modalities to fine-tune surgical outcomes and more recent CHED management strategies. Managing cases of CHED has been a challenge due to the dilemma in timing and appropriate surgical method selection and the lack of definitive medical or other conservative approaches. Currently, DSAEK has shown favorable results in cases of CHED. However, proper staging of CHED and selecting the appropriate management approach appears to play a critical role in managing such cases. Besides these, novel treatment modalities such as non-steroidal anti-inflammatory agents (NSAIDS) that target restoring water-flux activity in sub-type of CHED and gene editing using CRISPR-Cas9 are promising paradigm treatment modalities. We describe a systematic novel algorithm for the best long-term outcomes in cases of CHED.